Toxoplasmosis Treatment Drugs Market Report 2025

The toxoplasmosis treatment drugs market size has grown strongly in recent years. It will grow from $3.32 billion in 2024 to $3.52 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to limited treatment options, increased awareness of toxoplasmosis, growing prevalence of toxoplasmosis, expansion of healthcare infrastructure, evolving regulatory landscape.

The toxoplasmosis treatment drugs market size is expected to see strong growth in the next few years. It will grow to $4.44 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to research and development investments, emerging therapies for toxoplasmosis, increasing healthcare expenditure, global initiatives for infectious disease control, adoption of personalized medicine approaches. Major trends in the forecast period include development of combination drug therapies, integration of precision medicine in treatment strategies, emphasis on early diagnosis and intervention, customized treatment regimens, advances in drug delivery methods.

The increasing prevalence of toxoplasmosis infections is anticipated to drive the growth of the toxoplasmosis treatment drug market in the future. Toxoplasmosis refers to the infection and illness caused by the protozoan parasite Toxoplasma gondii in both humans and animals. The rise in toxoplasmosis infections heightens the demand for medications such as pyrimethamine, spiramycin, and leucovorin, which are used to treat patients with specific types of toxoplasmosis, thereby boosting the market for these treatment drugs. For example, in February 2024, data released by the UK Health Security Agency, a government organization in the UK, indicated that 54 confirmed cases of toxoplasmosis were reported in the second quarter of 2023, an increase from 37 cases during the same period in 2022. Consequently, the rising prevalence of toxoplasmosis infections is fueling growth in the toxoplasmosis treatment drug market.

The increasing geriatric population is expected to drive the growth of the toxoplasmosis treatment drug market in the future. Geriatrics focuses on the medical care of older individuals, a demographic that can be challenging to define precisely. Treating the geriatric population for toxoplasmosis requires a comprehensive approach. It is essential to balance efficacy with safety through personalized treatment plans, invest in research for new drugs and therapeutic methods, and emphasize prevention to ensure optimal care for older adults facing this infection. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a U.S.-based agency of the UN Secretariat, projected that the number of individuals aged 65 and older worldwide would more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. Thus, the growing geriatric population is driving the expansion of the toxoplasmosis treatment drug market.

Innovation in product offerings emerges as a prominent trend in toxoplasmosis treatment drugs. Leading companies in the market are actively developing advanced products to maintain their market position. An example of this trend is Meitheal Pharmaceuticals, a US-based pharmaceutical company, which, in September 2023, introduced Leucovorin Calcium for Injection in five different forms. These forms include single-dose vials containing 50 mg, 100 mg, 200 mg, 350 mg, and 500 mg. The intended use of leucovorin calcium for injection is in conjunction with high-dose methotrexate therapy for osteosarcoma.

Strategic investments are a key focus for major players in the toxoplasmosis treatment drug market. Such investments are made with a long-term objective, such as gaining a competitive edge, entering new markets, or developing innovative technologies. For instance, ASTRA Therapeutics, a UK-based drug development company, secured funding of CHF 150,000 ($173,787.15) in April 2023. This investment is earmarked for the development of therapies addressing parasite diseases such as malaria, cryptosporidiosis, and toxoplasmosis, which adversely affect millions of people globally and result in significant disease and productivity losses in cattle and agriculture.

In August 2023, Vyera Pharmaceuticals, LLC, a Switzerland-based pharmaceutical company, engaged in an asset purchase agreement with Phoenixus AG, a Swiss-based biopharmaceutical company. Through this agreement, both companies aim to sell the rights to Daraprim, a prescription drug containing pyrimethamine used for treating toxoplasmosis when combined with a sulfonamide, and Vecamyl, used to treat moderately severe to severe essential hypertension, as well as simple cases of malignant hypertension.

Major companies operating in the toxoplasmosis treatment drugs market include Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca plc, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals Inc., Lupin Ltd., Alvogen Group Inc, Manus Aktteva Biopharma LLP.

North America was the largest region in the toxoplasmosis treatment drugs market in 2024. The regions covered in the toxoplasmosis treatment drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the toxoplasmosis treatment drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Toxoplasmosis treatment drugs are pharmaceutical products or medications designed to manage infectious diseases caused by Toxoplasma gondii. These drugs are utilized to treat parasitic infections resulting from exposure to a common parasite found in cat feces and contaminated food.

The primary types of drug classes in the toxoplasmosis treatment drugs market include pyrimethamine, spiramycin, leucovorin, sulfadiazine, folic acid, and other variations. Chronic toxoplasmosis infection refers to a prolonged infection caused by the protozoan parasite Toxoplasma gondii. Indications for these drugs include both chronic toxoplasmosis infection and acute toxoplasmosis infection. The administration of these drugs can be through parenteral or oral routes and distribution occurs through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The toxoplasmosis treatment drugs market research report is one of a series of new reports that provides toxoplasmosis treatment drugs market statistics, including toxoplasmosis treatment drugs industry global market size, regional shares, competitors with a toxoplasmosis treatment drugs market share, detailed toxoplasmosis treatment drugs market segments, market trends and opportunities, and any further data you may need to thrive in the toxoplasmosis treatment drugs industry. This toxoplasmosis treatment drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The toxoplasmosis treatment drug market consists of sales of clindamycin and atovaquone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.